A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
about
Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug developmentOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerCancer Transcriptome Dataset Analysis: Comparing Methods of Pathway and Gene Regulatory Network-Based Cluster Identification.A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumorsTranslational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures.XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerFc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cellsTargeting the oncogenic Met receptor by antibodies and gene therapy.TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.Recent progress in protein-protein interaction study for EGFR-targeted therapeutics.Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancerBalancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy.Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeuticsA phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
P2860
Q21132280-0C06F4DA-2656-4AA7-8BAC-E36F16A49AD4Q28077545-FD4862F1-82F2-4DEA-BB89-7E51D75827F5Q33569864-343BBCD2-26D7-42BB-99D2-32869BA73D09Q33710008-FAC6C039-65AC-4D49-9AFB-D68ABAA85249Q33753135-F919F731-477B-48DE-8DD3-7672C4B8C04DQ35219539-4DBBBBAA-4A1B-4C0A-8E04-E07FEF1D2545Q37138970-03C2C10E-1715-4368-A7C0-B4F6A4849D17Q37589825-ED7DD2E8-276F-49A4-99E4-0DCCA6A6E984Q38216590-610100ED-227B-4CB0-89A4-E2421D8AF118Q38748906-5F734952-4E7B-4EDD-93BD-973891B7D7A0Q38782345-005F2A87-CE40-4439-AA1A-D7A9C90D511AQ38844694-586C2E0C-ED3A-4156-8708-FE27F5A065DFQ38861238-DBF2A798-00FC-4C2A-B31A-4BDF20301CF0Q38899428-169E693B-24F8-4849-B72B-30262D443571Q38937813-9479FE7D-9BCB-4714-A38A-66CD00EDF615Q42337044-05F7318E-94D1-4C0A-880E-04A3E56BCF94Q42499937-8511A93B-0DCC-47AC-A00C-FD22C732427BQ50882714-65A36CE8-E8D7-49B3-871A-B7BA07B0B576Q53789447-B56B067B-5643-4950-8208-4FF67DD33B58Q57151874-656D5802-C030-401F-AB2D-F5F8D6EB1470Q57162835-361ECF6D-AE6C-4F02-88A7-31E8220A8120
P2860
A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A novel bispecific EGFR/Met an ...... has potent antitumor activity.
@en
A novel bispecific EGFR/Met an ...... has potent antitumor activity.
@nl
type
label
A novel bispecific EGFR/Met an ...... has potent antitumor activity.
@en
A novel bispecific EGFR/Met an ...... has potent antitumor activity.
@nl
prefLabel
A novel bispecific EGFR/Met an ...... has potent antitumor activity.
@en
A novel bispecific EGFR/Met an ...... has potent antitumor activity.
@nl
P2093
P2860
P356
P1433
P1476
A novel bispecific EGFR/Met an ...... has potent antitumor activity.
@en
P2093
C Sustmann
G Niederfellner
M Asmussen
R Busl-Schuller
P2860
P2888
P304
P356
10.1038/ONC.2013.245
P407
P577
2013-07-01T00:00:00Z
P5875
P6179
1053661374